Effect of add-on therapy of tiotropium in COPD treated with theophylline

International Journal of COPD

Volumn 3, Issue 1, 2008, Pages 137-147

  Kawayama, Tomotaka ^a   Hoshino, Tomoaki ^a   Ichiki, Masao ^b   Tsuda, Toru ^c   Kinoshita, Masaharu ^d   Takata, Shohei ^e   Koga, Takeharu ^a   Iwanaga, Tomoaki ^a   Aizawa, Hisamichi ^a   Yokoyama, Toshinobu ^f   Kamimura, Tomoko ^f   Taguchi, Kazuhito ^g   Gohara, Rumi ^h   Tominaga, Yoshikazu ^h   Rikimaru, Toru ⁱ   Nishiyama, Mamoru ⁱ   Azuma, Koichi ^j   Matsunaga, Kazuko ^k   Koga, Hideyuki ^l  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c Tsuda Hospital   (Japan)

^d Nagata Hospital   (Japan)

^e FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^f KURUME UNIVERSITY   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^h Yame General Hospital   (Japan)

ⁱ Saiseikai Futsukaichi Hospital   (Japan)

^j Social Insurance Tagawa Hospital   (Japan)

^k National Hospital Organization Omuta Hospital   (Japan)

^l Keisinkai Hospital   (Japan)

more..

Author keywords

Chronic obstructive pulmonary disease; Combination therapy; Long acting anticholinergics agent; Slow relase theophylline; Tiotropium

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LONG ACTING DRUG; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADD ON THERAPY; ADULT; AGED; ANOREXIA; ARTICLE; BITTER TASTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HEMATURIA; HUMAN; LARYNX DISORDER; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PARESTHESIA; PEAK EXPIRATORY FLOW; PHARYNX DISEASE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SPIROMETRY; VOMITING; XEROSTOMIA;

AGED; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; DYSPNEA; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; THEOPHYLLINE; TREATMENT OUTCOME;

EID: 42149119568     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Akamatsu K, Yamagata T, Takahashi T, et al. 2007. Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist. Pulm Pharmacol Ther, 20:701-7.
2. Anzueto A, Tashkin D, Menjoge S, et al. 2005. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther, 18:75-81.
3. Aubier M, De Troyer A, Sampson M, et al. 1981. Aminophylline improves diaphragmatic contractility. N Engl J Med, 305:249-52.
4. Barnes PJ. 1997. Current therapies for asthma. Promise and limitations. Chest, 111:17S-26S.
5. Barnes PJ, Adcock IM and Ito K. 2005. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J, 25:552-63.
6. Bellia V, Foresi A, Bianco S, et al. 2002. Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: a double-blind, randomized, multicentre study (BREATH Trial). Respir Med, 96:881-9.
7. Brusasco V, Hodder R, Miravitlles M, et al. 2003. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax, 58:399-404.
8. Casaburi R, Mahler DA, Jones PW, et al. 2002. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J, 19:217-24.
9. Cazzola M, Gabriella Matera M. 2007. The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. Respir Med, 101:957-62.
10. Celli, B, Zu Wallack R, Wang S, et al. 2003. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest, 124:1743-8.
11. Cosio BG, Tsaprouni L, Ito K, et al. 2004. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med, 200:689-95.
12. Culpitt SV, de Matos C, Russell RE, et al. 2002. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 165:1371-6.
13. Di Marco F, Verga M, Santus P, et al. 2006. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med, 100:1925-32.
14. Disse B, Speck GA, Rominger KL, et al. 1999. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci, 64:457-64.
15. Donohue JF. 2005. Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc, 2:272-81; discussion: 90-1.
16. Dusser D, Bravo ML, Iacono P. 2006. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J, 27:547-55.
17. [GOLD] Global Initiative for Chronic Obstructive Lung Disease. 2006. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute [online]. Accessed 11 November 2006. URL: http://www.goldcopd.com.
18. Guidelines for the diagnosis and treatment of COPD, 2006. Guidelines for the diagnosis and treatment of COPD, 2nd edition. Committee for the second edition of the COPD guidelines of the Japanese Respiratory Society [online]. URL: http://www.jrs.or.jp/quicklink/glsm/guideline/ nopass_pdf/copd_summary_e.pdf.
19. Guyatt Gh, Townsend M, Pugsley So, et al. 1987. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis, 135:1069-74.
20. Hirano T, Yamagata T, Gohda M, et al. 2006. Inhibition of reactive nitrogen species production in COPD airways: comparison of inhaled corticosteroid and oral theophylline. Thorax, 61:761-6.
21. Hirata K, Nishimura M, Ichinose M, et al. 2003. Tiotropium once daily improves health status in Japanese patients with COPD. Am J Respir Crit Care Med, 167:A94.
22. Ichinose M, Nishimura M, Hirata K, et al. 2003. Tiotropium once daily improves spirometry over 24 hours in Japanese patients with COPD. Am J Respir Crit Care Med, 167:A95.
23. Ichinose M, Fukuchi, Y, Nagai, A, et al. 2006. Large-scale telephone survey on burden of patients with chronic obstructive pulmonary disease (COPD) in Japan: confronting COPD. Respirology, 11:A154.
24. Ito K, Lim S, Caramori G, et al. 2002. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA, 99:8921-6.
25. Jackson RH, McHenry JI, Moreland FB, et al. 1964. Clinical evaluation of elixophyllin with correlation of pulmonary function studies and theophylline serum levels in acute and chronic asthmatic patients. Dis Chest, 45:75-85.
26. Karpel JP, Kotch A, Zinny M, et al. 1994. A comparison of inhaled ipratropium, oral theophylline plus inhaled beta-agonist, and the combination of all three in patients with COPD. Chest, 105:1089-94.
27. Kelly HW. 1987. Theophylline toxicity. In: Jenne JW, Murphy S, Dekker M eds. Drug therapy for asthma. New York, pp 925-51.
28. Kobayashi, M, Nasuhara Y, Betsuyaku T, et al. 2004. Effect of low-dose theophylline on airway inflammation in COPD. Respirology, 9:249-54.
29. Mitenko PA, Ogilvie RI. 1973. Rational intravenous doses of theophylline. N Engl J Med, 289:600-3.
30. Moor-Jankowski J. 1976. Primate animals for biomedical research evaluation by the British Medical Research Council Laboratory Animal Centre. A critical review. J Med Primatol, 5:365-71.
31. Murciano D, Auclair MH, Pariente R, et al. 1989. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med, 320:1521-5.
32. Niewoehner DE, Rice K, Cote C, et al. 2005. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med, 143:317-26.
33. O'Donnell DE, Fluge T, Gerken F, et al. 2004. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J, 23:832-40.
34. Rodriguez-Roisin R. 2000. Toward a consensus definition for COPD exacerbations. Chest, 117:398S-401S.
35. Sullivan P, Bekir S, Jaffar Z, et al. 1994. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet, 343:1006-8.
36. Thirstrup S. 2000. Control of airway smooth muscle tone: II-pharmacology of relaxation. Respir Med, 94:519-28.
37. Tsukino M, Nishimura K, Ikeda A, et al. 1998. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax, 53:269-73.
38. Turner-Warwick M. 1957. Study of theophylline plasma levels after oral administration of new theophylline compounds. Br Med J, 2:67-9.
39. van Noord JA, Aumann JL, Janssens E, et al. 2006. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyper-inflation in patients with COPD. Chest, 129:509-17.
40. Vincken W, van Noord JA, Greefhorst AP, et al. 2002. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J, 19:209-16.
41. Zu Wallack RL, Mahler DA, Reilly D, et al. 2001. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest, 119:1661-70.